Home › Compare › VSSPY vs ABBV
VSSPY yields 13.95% · ABBV yields 3.06%● Live data
📍 VSSPY pulled ahead of the other in Year 1
Combined, VSSPY + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of VSSPY + ABBV for your $10,000?
Valid Soluções S.A. provides security printing services for payment and mobile solutions, identity solutions, digital marketing, and digital certification worldwide. It operates through Means of Payment, Identification, and Mobile segments. The Means of Payment segment offers integrated products and solutions, such as chip and magnetic stripe cards, gift cards, check printing, invoices, and bank statements, as well as solutions in radio frequency identification, contactless cards, and mobile payments. The Identification segment provides physical and electronic solutions, such as data collection, storage and management, security prints, recognition, and digital printing. Its solutions are used in the generation of computerized systems for the administration of databases, collection of biometric data, printing and customization of official identification documents, solutions for smart cities, and traceable stamps. The Mobile segment offers services of issuing statements and technologies for use in cell phones, and digital mobility, such as NFC, TSM, and HCE solutions for mobile service providers. It also develops technologies for use in cell phones, such as recharge and payment and production of cards intended for telecommunications. The company serves state governments and government agencies, large financial institutions, telecommunications companies, retailers, agriculture cooperatives, and self-employed professionals. The company was formerly known as Valid Soluções e Serviços de Segurança em Meios de Pagamento e Identificação S.A. and changed its name to Valid Soluções S.A. in August 2018. Valid Soluções S.A. was founded in 1957 and is headquartered in Rio de Janeiro, Brazil.
Full VSSPY Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.